Get The News

June 29th, 2020

Mennen Medical Ventures acquires additional 30% to raise its stake in CardioScale to 70%

Mennen Medical Ventures, the VC investment arm of Mennen Medical Group, has come to an agreement with CardioScale for an additional investment that will result in MMV owning 70% of the company. This increased stake will allow the company an even tighter integration with Mennen Medical to leverage its infrastructure of R&D, Logistics, Sales and Marketing. CardioScale shall use the latest investment to finance a new research and development program, as well as advanced clinical trials.


CardioScale develops a new technology that revolutionizes patient care by allowing medical professionals to predict deterioration in patients, even when their vital signs seem to be within normal range. This enables them to make informed decisions regarding intervention, and ultimately save lives.


June 10th, 2020

Randomix announces the establishment of GoaldenView LLC

Randomix, the media and entertainment arm of Redworth Capital Group, is proud to announce the establishment of its new fully owned subsidiary – GoaldenView LLC, which will focus on the development of sophisticated and unique algorithms to provide advanced analytical football data (soccer in the US).

The R&D of the project will be conducted in cooperation with Hippocampus, an Israeli leader in the field of digital marketing and data collection and analysis. Angelia Adzic, president of Randomix Group: “While sports statistics in general and soccer statistics in particular are flourishing in recent years, we are planning to concentrate on unique and unusual data and points of view, which are both fun and  thought-provoking for professionals, journalists and anyone who finds deep interest in this fascinating game.” At its R&D stage the project will be led by Dana Namerode, and the company is aiming to launch its data engine during the 2020/21 European season.

April 8th, 2020

AshconMed has entered into an exclusive distribution agreement with Mennen Medical for the Bilicare product line in Canada

AshconMed (Division of Ashcon International Inc.), a leading medical devices supplier in Canada, today announced that it has entered into an agreement with Mennen Medical Ltd. to be the exclusive distributor for the Bilicare product line in Canada.

“Utilizing a high-quality non-invasive transcutaneous bilirubin meter like the Bilicare, is the best method to expand and improve newborn jaundice screening processes,” said Javed Ashai, CEO of Ashcon International Inc. “We feel confident that by offering Bilicare to the Canadian market, we are giving our customers access to the most advanced practice in the most affordable price.”

“In the last couple of years we enjoyed great expansion of our worldwide coverage for our Bilicare product line.” said Danny Harel, CCO Mennen Medical Ltd. “In that perspective, we are very pleased to announce our agreement with AshconMed, a reputable company recognized for its innovations and unparalleled distribution of medical products to the medical community in Canada.”

The distribution agreement is effective immediately.

About AshconMed:

About Mennen Medical:

January 14th, 2020

Redworth Development completed the acquisition of an office buildings' complex in Uniontown, PA

Redworth Development has announced today that it completed the acquisition of an office buildings’ complex in Uniontown, PA. The complex consists of four buildings with a total area of about 50,000 sqf. The complex is located in a central location – next to Uniontown City hospital, which is a main medical services provider of the Fayette country and its surrounding areas. Most of the tenants are medical providers.

“This acquisition is in line with our intention to expand our assets’ portfolio in the commercial market, with a specific focus on special purpose properties. This location is unique and enables professionals that work in the hospital to provide additional services in a comfortable, nearby setting”, said Angelia Adzic, President of Redworth Development.

December 17th, 2019
Randomix Productions is excited to announce the wrapping of its first Hollywood feature film, “What Josiah Saw”

Robert Patrick, Nick Stahl And Tony Hale Among 6 Set For Psychological Horror ‘What Josiah Saw’

Robert Patrick (Scorpion), Nick Stahl (Sleepwalking), Scott Haze (Venom), Kelli Garner (Godzilla: King of the Monsters), Jake Weber (Midway) and Tony Hale (Veep) will star in Vincent Grashaw’s forthcoming psychological horror What Josiah Sawwhich has recently wrapped principal photography in Oklahoma. Written by Robert Alan Dilts, What Josiah Saw tells the story of a family with buried secrets who reunite at a farmhouse after two decades to pay for their past sins. Specific plot details are being kept under wraps. “I felt if I was ever going to do a film which scared people, it would need to be one grounded in a reality that was relatable,” Grashaw said. “It was one of the most unique and terrifying scripts I’d ever come across, and I can’t wait to share this one with an audience.” Randomix Productions’ Ran Namerode is producing alongside Beth Elise Hawk through her shingle, Gemini Girls Productions. Bernie Stern and Vincent Grashaw are also producing. Angelia Adzic and Cole Payne are executive producers. Patrick is repped by Gersh and Coronel Group; Nick Stahl is repped by LINK Entertainment and Fuller Law; Haze is repped by CAA, Thruline Entertainment, and attorney Darren Trattner; Garner is repped by Gersh and More/Medavoy; Weber is repped by Peg Donegan and Kimberly Hines at Framework Entertainment and Barry McPherson at APA; and Hale is repped by UTA and Hansen, Jacobson, Teller, Hoberman, Newman, Warren, Richman, Rush & Kaller.

November 21st, 2019

Mennen Medical's introduction of the DTR8 at MEDICA was a huge success

Mennen Medical introduced for the first time its revolutionary DTR8 Wearable (CVRI) Monitor at the MEDICA Conference in Dusseldorf, Germany.

The DTR8 is perfect for emergency use and fast response in combat / military, EMS, hospitals and first response teams scenarios such as terror attack evacuation, mass casualties events, multiple car accident and any other triage scenario.

The DTR8 is revolutionizing patient care by utilizing a wearable monitor including the CVRI Index, a proprietary breakthrough technology by another Redworth Capital Portfolio company – CardioScale. It is assessing hemodynamic change in patients, which serves as an add on to the vital signs monitoring, enabling medical staffs to make informed decisions regarding medical intervention and prioritizing patients.

“Re-sellers, medical teams, army representatives from more than 26 countries, showed great interest in the product.” Said Danny Harel, Redworth Capital CCO, “We are extremely excited about the DTR8, and are looking forward to brininging it to the markets early 2020.”

October 14th, 2019

CardioScale annuances that the Cardiovascular Reserve Index (CVRI) calculator receives a CE Mark approval

CardioScale is thrilled to announce that the Cardiovascular Reserve Index (CVRI) calculator has received a CE Marking approval

CE Marking allows clinical use of CVRI in the European Union (EU) and certain other countries that recognize CE Marking. This milestone should benefit both patients and physician users of our tech in Europe & other CE Mark countries.

CVRI stands for Cardiovascular Reserve Index. It detects hemodynamic changes regardless if the patient is compensated or not. CVRI is multi-vital sign index that results a numeric value of CVRI. It detects the hemodynamic change of an individual from his own defined CVRI baseline or from his previous CVRI measurement.

CVRI detects hemodynamic change even when each of the individual vital signs is within normal range and even during the compensated stage. CVRI is patient specific, it is agnostic (not hints to the underlying diagnosis) but directional (decrease CVRI means hemodynamic compromise, increase CVRI means hemodynamic improvement). It enables repetitive measurement and dynamic monitoring which enable pattern detection. The indication is of detecting a hemodynamic change in low risk populations. This is intended for use in patients who are being monitored, that otherwise appear stable, having neither clinical nor vital sign changes that raise concern. CVRI is an additional capability for apparently stable patients who are being monitored. If either clinical findings or vital signs raise concerns of deterioration, there is neither need nor indication to utilize CVRI.

The CVRI Calculator Complies with the dispositions of the directive 93/42/EEC and is classified as class IIa

May 26th, 2019

Redworth Development announces a new Real Estate development project in Sofia, Bulgaria

Redworth Development has announced today that it it joined forces with Home Town Development Ltd. to develop a new Real Estate project in Sofia, Bulgaria. The project shall include 60 luxury apartments and 2 commercial levels.

“Sofia’s Real Estate has grown remarkably in the last few years and presents a great potential”, said Ran Namerode, Chairman, Redworth Capital Group, “We believe that this will be a wonderful high-end commercial and residential combined project.”

We offer a unique opportunity to follow the progress of our project live 24/7



April 4th, 2019

Mennen Medical to acquire the assets of Adi Medical Ltd.

Mennen Medical, a global leading provider of high-end medical devices for a wide range of Hospital’s settings, announced today that it concluded the acquisition of the assets of Adi Medical Equipment Ltd., a developer and manufacturer of sophisticated powered medical carts specifically designed for healthcare and clinical environments.

“Medical carts became an integral part of streamlining workflow solutions in the modern healthcare settings,” said Mr. Ran Namerode, Chairman of Mennen Medical. “The medical carts’ business has been growing fast in the USA and other major markets in recent years and is expected to continue growing at a high pace. This increasing demand presents a great opportunity to companies that can offer a high-end sophisticated solution. We believe that Adi Medical’s products are perfectly suited to address this need.”

“I am pleased with this opportunity to bring together Adi Medical’s expertise and superb products and Mennen’s long history of leadership in the medical devices arena.” said Mrs. Nava Botvinik, CEO of Adi Medical.  “I am confident that this combination will result in positioning Adi Medical’s products as global leaders in this category.”

October 9th, 2018

CardioScale Wins CERPrize 2018!

Hôtel de Ville, Paris – Conference of European Rabbis greeted by French Technology Minister as they embrace the internet as a force for good. The event, which is under the patronage of the Prime Minister of France, Mr Édouard Philippe and Mrs. Anne Hidalgo, the Mayor of Paris, brings together talented and ambitious entrepreneurs together with Europe’s most senior Rabbis to encourage using the internet for social good.

This years’ winner, selected from over 500 applications, is Israeli born Moaz Ben Ari, whose creation of the CardioScale Ltd. system revolutionises patient care by allowing medical professional to predict deterioration in patients, even when their vital signs are within normal range. This enables them to make informed decisions regarding intervention, and ultimately, help save lives.

June 21st, 2018

CardioScale Won First Prize In The 2018 Combating Terrorism Technology Startup Challenge

CardioScale Ltd. won first place and $100,000 prize with a device that will provide an early detection of hemodynamic deterioration after injury.

Its embedded proprietary medical monitoring algorithm in a portable device enables dramatic improvements in triaging, monitoring, and therefore survival rates of victims of terrorist attacks and other mass-casualty events.

Combat Terrorism Technology Startup Challenge  (CTTSC3) is a unique contest to identify startups with technologies that can help defeat terrorism.

CTTSC3 was organized by the US Department of Defense, Combating Terrorism Technical Support Office, together with the Israel Ministry of Defense, Directorate of Defense Research and Development and the MIT Enterprise Forum of Israel. 130 start-ups competed and the winner was decided by a team of 55 judges.

June 20th, 2018

Belmont Instrument, LLC Announced It Has Acquired MTRE Ltd. Product Lines From Mennen Medical Ltd.

Belmont Instrument, LLC (“Belmont“) announced it has acquired MTRE Advanced Technologies Ltd. (“MTRE”) product lines from Mennen Medical Ltd. MTRE, headquartered in Yavne, Israel, is an advanced developer and manufacturer of non-invasive solutions for body temperature management. Terms of the transaction were not disclosed.

Belmont’s acquisition of MTRE extends its portfolio to include non-invasive body temperature management solutions and advances Belmont’s strategy to invest in technologies that leverage the company’s existing product portfolio and sales channels. MTRE’s normothermia management product line includes the Allon® system and ThermoWrap® disposable garment, and MTRE’s temperature management portfolio includes the CritiCool® system and CureWrap™. These non-invasive solutions are designed to enable healthcare providers to exercise precise control of body temperature, allowing for significant medical and economic benefits. The portfolio targets a wide range of medical applications and disciplines. Specifically, the Allon system is indicated for use in hospital invasive and coronary care units, operating, recovery and emergency rooms, burn units, and on medical and surgical floors. CritiCool is a thermo regulating system indicated for monitoring and controlling patient temperature. CritiCool is commonly used in procedures where there is a need for Target Temperature Management. Both the ThermoWrap and CureWrap lines of disposable garments are available in adult, pediatric, and infant sizes.

Brian Ellacott, Chief Executive Officer, Belmont, stated, “We are very pleased to bring the MTRE patient temperature management portfolio to healthcare providers worldwide and to the Belmont family. This is the first among several planned strategic acquisitions for Belmont as we build out a strong global product portfolio to better support clinicians and leverage our core strengths in anesthesiology, critical care and trauma to broaden the availability of these products in the market.”

Ran Namerode, Chairman, Mennen Medical Group, stated, “We are thrilled to engage with Belmont in this transaction that will accelerate the growth of MTRE’s temperature management portfolio to benefit more patients globally.”